Rare telomere and non-telomere genetic variants significantly affect survival in IPF patients, with non-additive effects on common risk variants. Polygenic risk scores (PRS-IPF) may play a crucial ...

The overall cough in idiopathic pulmonary fibrosis market is expected to rise due to increasing prevalent cases over the globe and thus the surge in treatment options. The expected launch of emerging ...

New York, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2029 ...

Researchers used integrated genomics to identify convergent transcriptomic pathways in emphysema and IPF. Convergent transcriptional regulatory networks in diseases such as chronic obstructive ...

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional ...

Clinical Trial Results in Pulmonary Medicine Advance Outcomes session, TETON-1 evaluated inhaled treprostinil in patients with idiopathic pulmonary fibrosis, a progressive disease associated with ...

Jascayd approval has been granted in Japan and recommended in the European Union for treating adults with two types of pulmonary fibrosis.

An Insilico Medicine drug candidate spawned by the company’s artificial intelligence technology now has clinical data showing breathing improvement in patients who have a debilitating lung disorder.

Not intended for US and UK media Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive ...

Please provide your email address to receive an email when new articles are posted on . Thirty-eight percent of patients with IPF and OSA died, whereas this rate was 46% in patients with IPF only.